This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, PYRGF, OSTX, ELYM, and ATNMShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Eliem Therapeutics (ELYM), and Actinium Pharmaceuticals (ATNM). Stellar Biotechnologies vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Stellar Biotechnologies (NASDAQ:SBOT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends. Does the media refer more to SBOT or AVTE? In the previous week, Stellar Biotechnologies' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score. Company Overall Sentiment Stellar Biotechnologies Neutral Aerovate Therapeutics Neutral Which has better valuation and earnings, SBOT or AVTE? Stellar Biotechnologies has higher revenue and earnings than Aerovate Therapeutics. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K260.41-$5.03M-$1.76-5.83Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.41 Is SBOT or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders and institutionals believe in SBOT or AVTE? 1.7% of Stellar Biotechnologies shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryStellar Biotechnologies beats Aerovate Therapeutics on 5 of the 9 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.69M$806.49M$5.73B$9.80BDividend YieldN/A4.84%4.54%4.08%P/E Ratio-5.831.1530.7425.12Price / Sales260.4125.58441.05108.85Price / CashN/A19.5637.3459.16Price / Book4.846.588.886.24Net Income-$5.03M-$4.93M$3.26B$265.56M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$10.26+5.7%N/A-13.0%$54.69M$210K-5.8325High Trading VolumeAVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-88.2%$214.49MN/A-2.4720High Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-41.4%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.4202 of 5 stars$7.62+5.0%$85.00+1,015.5%N/A$179.52MN/A-1.7450News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.50+3.7%N/AN/A$161.33MN/A0.00N/AVIRIVirios TherapeuticsN/A$4.77-2.5%$5.00+4.8%+2,508.5%$91.86MN/A-17.675WHWKWhitehawk TherapeuticsN/A$1.73+2.4%N/AN/A$81.54M$25.98M-28.8340PYRGFPyroGenesis CanadaN/A$0.28+4.2%N/A-59.5%$51.76M$9.14M-4.6090OSTXOS Therapies2.2248 of 5 stars$1.78+6.3%$18.00+914.1%-37.4%$49.87MN/A-2.06N/ANews CoverageELYMEliem TherapeuticsN/A$1.65-2.9%N/A-69.1%$49.09MN/A-3.119Gap UpATNMActinium Pharmaceuticals2.9331 of 5 stars$1.52+3.4%$4.50+196.1%-6.0%$47.42MN/A-1.0930Positive NewsShort Interest ↓ Related Companies and Tools Related Companies AVTE Competitors NLTX Competitors CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors PYRGF Competitors OSTX Competitors ELYM Competitors ATNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access